 Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that since the May 1st, 2020 temporary suspension by the Securities and Exchange Commission SEC of trading in the securities of Moleculin Biotech, Inc. MBRX, additional information has come to the Companys attention regarding claims disseminated by third parties. 